Phase 1 Clinical Study for Evaluating the Safety and Efficacy of a Transdermal Injection of JX-594 (Thymidine Kinase (-)/GM-CSF(+) Vaccinia Virus) Within the Tumor of Patients With Hepatic Carcinoma

Trial Profile

Phase 1 Clinical Study for Evaluating the Safety and Efficacy of a Transdermal Injection of JX-594 (Thymidine Kinase (-)/GM-CSF(+) Vaccinia Virus) Within the Tumor of Patients With Hepatic Carcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2013

At a glance

  • Drugs Pexastimogene devacirepvec (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jul 2008 Results for three patients with liver cancer published in Molecular Therapy in July 2008
    • 27 Feb 2008 Results have been reported at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference.
    • 27 Feb 2008 Added sponsor, from NCT record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top